


PERSONAL INFORMATION



Dott.ssa Lucia Sara D'Angiolella



WORK EXPERIENCE

January 2020 – ongoing

Market Access & Pricing Advisor

Novo Nordisk Spa - Via Elio Vittorini, 129 – 00144 – Rome, Italy

- Support global pricing policies and contribute to their implementation within the local environment
- Support the preparation of the P&R dossier both for new products and new indications of already marketed products
- Contribute to communication strategies to be addressed to regional stakeholders by Field Market Access Advisors
- Adapt/realize ad hoc promo materials/services/legal documents to be used by Field Market Access Advisor colleagues with regional stakeholders
- Monitor information and market access dynamics to support access acceleration in each Region by producing ad hoc analyses and reports when needed
- Manage Italian prices information data base and contribute to implementation of price changes
- Support the preparation of ad-hoc dossiers for products inclusion in regional formularies
- Prepare Price Business Cases in connection with Europe and Global HQ
- Prepare Budgets and Business plans for all products
- Perform Health Technology Assessment analysis

Application area: rare disease, growth disorders, diabetes, obesity

Topic: Market Access, Pricing, Health Technology Assessment

May 2016 – January 2020

Market Access Senior Consultant – Focus on Health Technology Assessment

Fondazione Charta - Center for Health Associated Research and Technology
Via Visconti di Modrone, 18 – 20122 – Milan, Italy

- Develop evidence and strategy in Market Access, successful Health Technology Assessment (HTA) assessments, optimal pricing, reimbursement and formulary listing
- Develop oPatient-Reported Outcome (PRO) measurement and application
- Develop Global Value Dossier (GVD), reimbursement dossier, economic models (core model, Markov model, decisional model, budget impact model), retrospective database analyses, real life evidence data collection and analysis, costing
- Implement clinical trials and manage Research Ethics Committees
- Perform systematic literature review
- Perform GRADE (Grading of Recommendations, Assessment, Development and Evaluations) evaluation for making clinical practice recommendations

Application area: rare disease, hematology, oncology, respiratory disease, rheumatology, diabetes
Topic: Public Health, Epidemiology, Health Technology Assessment

April 2014 – April 2016

Health Economic Research Assistant

EIHTA - European Institute for Health Technology Assessment
Via Serafino Balestra 33, 6901 Lugano, Switzerland

- Research epidemiological, clinical, humanistic, economic and organizational evidences on new drugs and technologies
- Manage and conduct clinical trial, original research, seminars, conferences, courses or other educational and training events
- Develop comprehensive pre-launch planning, including key organizational strategies, regulatory considerations, global issues, and methods for ensuring the most effective plans
- Develop GVD, pharmacoeconomic model and HTA report

Application area: rare disease, hematology, oncology, respiratory disease, rheumatology, diabetes
Topic: Epidemiology, Health Technology Assessment

September 2010 – March 2014

Market Access Junior Consultant – Focus on Health Technology Assessment

Fondazione Charta - Center for Health Associated Research and Technology
Via Visconti di Modrone, 18 – 20122 – Milan, Italy

- Develop evidence and strategy in Market Access, successful Health Technology Assessment (HTA) assessments, pricing and reimbursement
- Develop Global Value Dossier (GVD), economic models (core model, Markov model, decisional model),
- Develop depth understanding of therapeutic area strategies, disease areas, relevant clinical, patient, payer, and reimbursement landscapes, market/customer landscape, and emerging policy issues.
- Develop health economic and outcomes research (HEOR) studies, real-world evidence (e.g., burden of illness studies, treatment patterns, quality of care etc.).
- Develop, conduct, oversee and manage primary and secondary studies and HEOR models and appropriate tools to support access decisions (budget impact model, reimbursement dossier, delphi panel)

Application area: rare disease, hematology, oncology, respiratory disease, rheumatology, diabetes, chronic disease
Topic: Pharmacoeconomy, Health Technology Assessment

January 2009 - June 2009

Trainer

Farmacia Comunale
Via Vittorio Emanuele, 106, 81030 Parete CE

- Implement galenic laboratory preparations
- Manage prescription, dispensing and customer request services
- Manage communications tools, supply chain, procurement and aftersales

Application area: preparation and dispensation of medication,
Topic: Territorial service and Public Health

EDUCATION AND TRAINING

January 2019 - September 2019

Contract Teacher

University of Milan Bicocca Milan

- Teaching, mentoring and coaching

Application area: Determinant of health, health economy, clinical trial, systematic literature review

Topic: Hygiene, Preventive Medicine and Public Health

January 2019 - September 2019 **Research Fellow**

University of Federico II Naples

- Analyze and implement health management processes
- Perform epidemiological and clinical studies and systematic literature review
- Perform Health Technology Assessment (HTA) analyses

Application area: Health economy, clinical trial, systematic literature review in chronic degenerative prevention

Topic: Preventive Medicine and Public Health

October 2016 - December 2018 **PhD in Public Health**

University of Milan Bicocca Monza

- Implement health economic models and Health Technology Assessment Analyses
- Analyze large data sets using exploratory, descriptive and multivariate analysis techniques, using R software
- Conduct survey, clinical studies and systematic literature review
- Provide oral explanations at several local, national, and international scientific conference
- Prepare and review manuscripts for submission to scientific journals

Application area: Health economy, clinical trial, systematic literature review

Topic: Health Technology Assessment and Public Health

September 2004 – July 2010

Doctor of Pharmacy

University of Federico II Naples

- Main topic: Pharmacoeconomy

PERSONAL SKILLS

Mother Tongue

Italian

Other language(s)

| UNDERSTANDING | | SPEAKING | | WRITING |
|---------------|---------|--------------------|-------------------|---------|
| Listening | Reading | Spoken interaction | Spoken production | |
| English | C1 | C1 | C1 | C1 |
| German | A1 | A1 | A1 | A1 |

Levels: A1 and A2: Basic user - B1 and B2: Independent user - C1 and C2: Proficient user
Common European Framework of Reference for Languages

COMMUNICATION SKILLS

Public speaking, relator and visiting lecturer

**ORGANISATIONAL/
MANAGERIAL SKILLS**

Orientation to teamwork, strong leadership and communication skills to manage complex projects and multiple priorities, problem solving, effective time and stress management

JOB-RELATED SKILLS

Health Economy, Epidemiology, Public Health, Clinical Trial, Health Technology Assessment, Outcomes Research, Patient Reported Outcome, Prevention, Chronic disease, Rare disease, Oncology, Rheumatology, Diabetes, Hemophilia

INFORMATIC SKILLS

Office, R, EndNote, PlotDigitizer

INTEREST

Sport, slow-food and nature, art, hospital clown volunteer, innovation science

PUBLICATIONS

"Italy's health performance, 1990–2017: findings from the Global Burden of Disease Study 2017". GBD 2017 Italy Collaborators. *Lancet Public Health*; 2019. 0(0):1-13. [https://doi.org/10.1016/S2468-2667\(19\)30189-6](https://doi.org/10.1016/S2468-2667(19)30189-6).

"Cost Minimization Analysis of Radiofrequency Compared to Laser Thermal Ablation in Patients with Hepatocellular Carcinoma". Guarino M, D'Angiolella LS, Falco L, Morando F, Di Costanzo GG, Morisco F, Improta G, Mantovani LG, Caporaso N. *Farmeconomia. Health economics and therapeutic pathways*, 2019. 20(1): 43-50. <https://doi.org/10.7175/fe.v20i1.1401>

"The ESC Textbook of Cardiovascular Medicine European Society of Cardiology Health and economic impact of non-adherence to preventative cardiovascular medicines. Economics of new therapies in electrophysiology. Economics of new therapies for heart failure, atrial fibrillation, and hypercholesterolaemia". Oxford 2018.

"The socio-economic burden of patients affected by Hemophilia with inhibitors". D'Angiolella LS, Cortesi PA, Rocino A, Coppola A, Hassan HJ, Giampaolo A, Solimeno P, Lafranconi A, Micale M, Mangano S, Crotti G, Pagliarin F, Cesana G, Mantovani LG. *Eur J Haematol*. 2018; 101(4):435-456. doi: 10.1111/ejh.13108.

"Costs and effectiveness of influenza vaccination: a systematic review" D'Angiolella LS, Lafranconi A, Cortesi PA, Rota S, Cesana G, Mantovani LG. *Ann Ist Super Sanita*. 2018;54(1):49-57. doi: 10.4415/ANN_18_01_10.

"Stroke prevention, 1-year clinical outcomes and healthcare resource utilization in patients with atrial fibrillation in France: Data from the GARFIELD-AF registry". Le Heuzey JY, Bassand JP, Berneau JB, Cozzolino P, D'Angiolella L, Doucet B, Mantovani LG, Martelet M, Mouallem J, Muller JJ, Pieper K; GARFIELD-AF Investigators. *Arch Cardiovasc Dis*. 2018 May 31. pii: S1875-2136(18)30089-5. doi: 10.1016/j.acvd.2018.03.012.

"Cost and Cost Effectiveness of Treatments for Psoriatic Arthritis: A Systematic Literature Review" D'Angiolella LS, Cortesi PA, Lafranconi A, Micale M, Mangano S, Cesana G, Mantovani LG. *Pharmacoeconomics*. 2018;36(5):567-589. doi: 10.1007/s40273-018-0618-5.

"Modern Treatments of Haemophilia: Review of Cost-Effectiveness Analyses and Future Directions" Cortesi PA, D'Angiolella LS, Lafranconi A, Micale M, Cesana G, Mantovani LG. *Pharmacoeconomics*. 2018;36(3):263-284. doi: 10.1007/s40273-017-0588-z.

"Obsessive Compulsive Tic Disorder: appropriate diagnosis and treatment as key elements to improve health and rationalize use of resources" Scalone L, D'Angiolella LS, Mantovani LG, Galentino R, Servello D, Dell'Osso B, Zanaboni CD, Porta M. *Epidemiology, Biostatistics and Public Health*. 2017,14(4). doi: <https://doi.org/10.2427/12661>

"Use of Kovaltry® in patients with Hemophilia A: clinical and economical aspects from the pivotal clinical trials" D'Angiolella LS, Molinari AC, Cortesi PA, Coppola A, Mantovani LG. *Farmeconomia. Health economics and therapeutic pathways* 2018, 18 (1). doi: <https://doi.org/10.7175/fe.v18i1.1284>.

"Nintedanib for the treatment of idiopathic pulmonary fibrosis in Italy" Belisari A, Bettoni D, Cortesi PA, D'Angiolella LS, Mantovani LG. *Farmeconomia. Health economics and therapeutic pathways* 18(1S):3-41. <https://doi.org/10.7175/fe.v18i1S.1300>.

"Sacubitril/valsartan in heart failure with reduced ejection fraction: cost and effectiveness in the Italian context." D'Angiolella LS, Cortesi PA, Pitotti C, Ritrovato D, Mantovani LG, Senni M. *Eur J Heart Fail.* 2017;19(11):1551-1553. doi: 10.1002/ejhf.919.

"Cost-effectiveness analysis of oral fentanyl formulations for breakthrough cancer pain treatment" Cortesi PA, D'Angiolella LS, Vellucci R, Allegri M, Casale G, Favaretti C. *PLoS One.* 2017;12(6):e0179523. doi: 10.1371/journal.pone.0179523.

"Cost-effectiveness analysis of ocriplasmin in the treatment of vitreomacular traction in Italy" D'Angiolella LS, Miglietta R, Bandello F, Rizzo S, Mantovani LG. *Farmeconomia. Health economics and therapeutic pathways.* 2015; 16(4):93-102. <https://doi.org/10.7175/fe.v16i4.1221>

"Economic impact of the use of Hyalubrix® in the treatment of hip osteoarthritis in Italy" Migliore A, Belisari A, D'Angiolella LS, Bizzi E, Massafra U, Piscitelli P, Mantovani LG. *Farmeconomia. Health economics and therapeutic pathways.* 2014; 15(4):139-146. <http://dx.doi.org/10.7175/fe.v15i4.977>

"Italian population-based values of EQ-5D health states" Scalone L, Cortesi PA, Ciampichini R, Belisari A, D'Angiolella LS, Cesana G, Mantovani LG. *Value Health.* 2013;16(5):814-22. doi: 10.1016/j.jval.2013.04.008.

"Systemic vasculitis: how little we know about their societal and economic burden" Trieste L, Palla I, Baldini C, Talarico R, D'Angiolella L, Mosca M, Turchetti G. *Clin Exp Rheumatol.* 2012; 30(S73): 154-156.

"Systematic literature review on economic implications and pharmacoeconomic issues of psoriatic arthritis" Cortesi PA, Scalone L, D'Angiolella L, Belisari A, Fusco F, Olivieri I, Mantovani LG. *Clin Exp Rheumatol* 2012; 30(S73):126-S131.

"Cetuximab in first line treatment of metastatic colorectal cancer" Barone C, Belisari A, Ciardiello F, Mantovani L, D'Angiolella L, Furneri G, Normanno N, Piacentini P, Pinto C. *Farmeconomia. Health economics and therapeutic pathways,* 2012; 13(1S):1-80 <http://journals.edizioniseed.it/index.php/FE/article/view/305>

"Impatto di Budget derivante dall'uso di Alitretinoina" Belisari A, De Pità O, D'Angiolella LS. *Health Technology Assessment; Supplemento de "Il Sole 24 Ore Sanità"* p. 161-178 <http://www.ibs.it/code/9788832476699/mantovani-lorenzo/health-technology-assessment.html>

Poster presentation

"PSY95-Exploring the potential cost-effectiveness of emicizumab for hemophilia a with inhibitor in Italy" D'Angiolella LS, Cortesi PA, Ferrario M, Cesana G, Mantovani LG. *Value in Health* 2018 21, S452.

"PND41-Healthcare costs of patients with spinal muscular atrophy" D'Angiolella LS, Belisari A, Mantovani LG, Sansone V, Vita G, Pane M. *Value in Health* 2018 21, S336.

"PSY42-Exploring The potential budget impact of emicizumab for hemophilia a with inhibitor in Italy". Cortesi PA, D'Angiolella LS, Ferrario M, Cesana G, Mantovani LG. Value in Health 2018 21, S442-S443.

"156 ATTD8-0266. Burden of severe Hypoglycemia and Ketoacidosis in patients with Type 1 Diabetes Mellitus: morbidity, mortality and costs". Cozzolino P, D'Angiolella LLS, Bosi E, Scavini M, Mantovani LG. The Official Journal of ATTD, 2018, A-74.

"P049 EAHAD. Clinical Review of pivotal trials on octocog-alfa (Kovaltry) and other recombinants FVIII in patients with Hemophilia A. D'Angiolella LS, Molinari CA, Cortesi PA, Coppola A, Mantovani LG". Haemophilia 2018.

COURSE AND CONGRESS

ISPOR 20th Europe 2018 The leading conference for health economics and outcomes research 10-14 November 2018 Barcelona, Spain

50° Congresso SITI Società Italiana di Igiene, Medicina Preventiva e Sanita' Pubblica, 22-25 November 2018 Torino, Italy

ISPOR 19th Annual European Congress A cura di: International Society for Pharmacoeconomics and Outcomes Research 29 October - 2 November 2016 Vienna, Austria

49° Congresso Nazionale SITI Società Italiana di Igiene, Medicina Preventiva e Sanita' Pubblica 16-19 November 2016 Napoli, Italy

Summer School UCL Health and Society Summer School: Social Determinants of Health University College London 3-6 July 2016 London, UK.

ISPOR 18th Annual European International Society for Pharmacoeconomics and Outcomes Research 7-11 November 2016 Milano, Italy

Life Sciences Industry Ministry of Health U.S 22 October 2014 Roma, Italy

ISPOR 15th Annual European Congress: "Introduction to Retrospective Database Analysis" 3 November 2012, Berlin, Germany

ISPOR 15th Annual European Congress "Introduction to Patient Preference Methods Used for QALYs" 3 November 2012, Berlin, Germany

ORDERS AND ASSOCIATION

From November 2017 SItI - Societa' Italiana Igiene Medicina Preventiva e Sanita' Pubblica

From November 2015 ISPOR (International Society For Pharmacoeconomics and Outcomes Research)

From May 2014 AIFOR (Associazione Italiana di Farmacoeconomia e Outcomes Research)

From January 2011 Ordine dei Farmacisti della Provincia di Napoli